Your browser doesn't support javascript.
loading
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa.
Wu, Shuanzhi; Wang, Tenghua; Li, Jieyun; Zhang, Zhixin; Li, Chen; Xiao, Shuangshuang; He, Jin; Wang, Xuan; Hu, Zhiqin; Wang, Xiaole; Zheng, Sichao; Liang, Xintong; Chen, Guiying; Li, Yongmei; Li, Xianbo; Zhan, Yaoxuan; Zou, Qinwen; Jiang, Hongliang; Zheng, Qingshan; Ban, Li; Liu, Haiyan; Fang, Yi.
Afiliação
  • Wu S; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Wang T; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Li J; Beijing Lianxin Pharmaceutical Co., Ltd, Beijing, China.
  • Zhang Z; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Li C; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Xiao S; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • He J; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Wang X; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Hu Z; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Wang X; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Zheng S; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Liang X; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Chen G; Wuhan Hongren Biomedical Co., Ltd, Wuhan, China.
  • Li Y; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Li X; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Zhan Y; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Zou Q; Beijing Lianxin Pharmaceutical Co., Ltd, Beijing, China.
  • Jiang H; Wuhan Hongren Biomedical Co., Ltd, Wuhan, China.
  • Zheng Q; Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Ban L; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Liu H; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Fang Y; Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Expert Opin Investig Drugs ; 32(11): 1085-1094, 2023.
Article em En | MEDLINE | ID: mdl-37955047
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator Xa / Anticoagulantes Limite: Adult / Humans Idioma: En Revista: Expert Opin Investig Drugs Assunto da revista: TERAPIA POR MEDICAMENTOS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator Xa / Anticoagulantes Limite: Adult / Humans Idioma: En Revista: Expert Opin Investig Drugs Assunto da revista: TERAPIA POR MEDICAMENTOS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China